Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) will be ...

†High patient compliance after training. ‡Likely to be preferred for frail patients. Adapted from [34].

These analyses support the Company's understanding of ampreloxetine's highly selective mechanism of action and potential to address symptoms of neurogenic orthostatic hypotension (nOH) in patients ...

Orthostatic hypotension (OH) is a common disorder in older adults. The pathophysiology of OH in older adults occurs commonly as a consequence of decreased effective circulating volume and/or ...

Cost to be about $2,100 per month less than the average cost 1 for someone with Medicare Part D Starting today, CivicaScript will offer droxidopa 300 mg capsules for sale to pharmacies for $132 ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

ATH434 is designed to reduce α-synuclein aggregation and oxidative stress by binding to and redistributing excess loosely bound iron in the brain.

While most people are familiar with the dangers of high blood pressure, low blood pressure often flies under the radar because it's typically asymptomatic. Low blood pressure is also not a ...

Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity ...

Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA - MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeuti ...